Back to top
more

Rite Aid Corporation (RAD)

(Delayed Data from NYSE)

$8.77 USD

8.77
1,437,900

-0.03 (-0.34%)

Updated May 3, 2019 04:02 PM ET

After-Market: $8.75 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Is the Options Market Predicting a Spike in Rite Aid (RAD) Stock?

by Zacks Equity Research

Investors need to pay close attention to Rite Aid (RAD) stock based on the movements in the options market lately.

    Rite Aid (RAD) Posts In-Line Q2 Loss, Tops Sales, Alters Board

    by Zacks Equity Research

    Rite Aid's (RAD) second-quarter fiscal 2019 loss per share matches estimates while revenues beat. The company reshuffles its board and governance in response to the failed Albertsons merger.

      Titan Machinery, Pilgrim's Pride, Nike, Rite Aid and BlackBerry highlighted as Zacks Bull and Bear of the Day

      by Zacks Equity Research

      Titan Machinery, Pilgrim's Pride, Nike, Rite Aid and BlackBerry highlighted as Zacks Bull and Bear of the Day

        Ryan McQueeney headshot

        Upcoming Earnings to Watch: NKE, RAD, BB

        by Ryan McQueeney

        U.S. stocks saw a mostly positive week after Wall Street shrugged off early concerns about escalating trade tensions., but will any of the earnings reports coming in the next few days have enough positive news to outweigh other headwinds?

          Will Generic Market Trends Mar Rite Aid (RAD) Q2 Earnings?

          by Zacks Equity Research

          Rite Aid (RAD) is struggling as evident from its dismal earnings and sales graphs. Additionally, unfavorable trends in the generic drug market are likely to impact the company's results for fiscal 2019.

            Urmimala Biswas headshot

            Stay-at-Home Stocks Find Favor With New Age Investors

            by Urmimala Biswas

            Gradually changing lifestyle of people indicates that they are keen on staying indoors and availing products and services that are delivered to them.

              Options Traders Expect Huge Moves in Rite Aid (RAD) Stock

              by Zacks Equity Research

              Rite Aid (RAD) needs investors to pay close attention to the stock based on moves in the options market lately.

                How Will Rite Aid Be Impacted by Albertsons Deal Termination?

                by Zacks Equity Research

                Rite Aid (RAD) and Albertsons mutually terminate their pending merger deal. Currently, Rite Aid is on track to leverage on its growth strategies as a standalone company.

                  Rite Aid Stock Falls on FY19 View Cut Ahead of Merger Vote

                  by Zacks Equity Research

                  Rite Aid (RAD) lowers fiscal 2019 guidance as the generic drug purchasing efficiencies fall below expectations. Rite Aid shareholders are likely to vote for the Albertsons merger on Aug 9.

                    Are Options Traders Betting on a Big Move in Rite Aid (RAD) Stock?

                    by Zacks Equity Research

                    Investors in Rite Aid (RAD) need to pay close attention to the stock based on moves in the options market lately.

                      Benjamin Rains headshot

                      Buy Walgreens (WBA) Stock Because It's Cheap & Amazon Fears Are Overblown?

                      by Benjamin Rains

                      Shares of Walgreens Boots Alliance (WBA) are down 16.5% over the last year based mostly on Amazon (AMZN) fears. There is no doubt that online selling and delivery have altered the retail world, but does that mean Walgreens can no longer compete? Let's dive into some of WBA's fundamentals to see what to do with the stock.

                        Rite Aid (RAD) Stock Picks Momentum: Will It Scale Higher?

                        by Zacks Equity Research

                        Rite Aid (RAD) gathers momentum on pending merger with Albertsons, the sale of assets to Walgreens, lesser debt burden and a robust outlook.

                          Sweta Jaiswal headshot

                          Amazon Forays Into Pharmacy Business: Red Alert for Others?

                          by Sweta Jaiswal

                          Amazon's entry into the high-potential pharmaceutical industry deals a blow to share prices of major players.

                            Sapna Bagaria headshot

                            Will Healthcare Buck Up on Amazon's Pillpack Takeover Deal?

                            by Sapna Bagaria

                            Amazon's (AMZN) use of technology, innovative strategies and skilled leadership should take it far in the healthcare space.

                              Madeleine Johnson headshot

                              NKE Beats Earnings, Spotify's Video Push, & AMZN's Big Pharma Purchase

                              by Madeleine Johnson

                              On today's episode of the Zacks Friday Finish Line, Editor Maddy Johnson is joined by Ben Rains, an Associate Stock Strategist here at Zacks, to take on this week's biggest stories, including Nike's latest quarterly earnings results, Spotify's media ambitions, and Amazon's latest assault on the healthcare industry.

                                Afrasiab Mian headshot

                                After a Historic Rise, Should You Still Buy Amazon (AMZN) Stock?

                                by Afrasiab Mian

                                With massive growth already baked into its stock price, many investors may feel that Amazon stock is too expensive and that they have missed their chance to cash in. Is this truly the case? Let's take a look.

                                  Benjamin Rains headshot

                                  Investors Shouldn't Panic About Amazon's PillPack Purchase

                                  by Benjamin Rains

                                  Shares of pharmacy giants CVS (CVS), Rite Aid (RAD), and Walgreens Boots Alliance (WBA) all plummeted on Thursday morning after Amazon (AZMN) announced its purchase of online pharmacy delivery startup PillPack. The move clearly has some investors worried that Amazon's push into the pharmaceutical industry will hurt the current powers. So let's take a look at more of the details to find out what's really going on.

                                    Rite Aid (RAD) Reports Q1 Loss, Stock Up on Revenue Beat

                                    by Zacks Equity Research

                                    Rite Aid (RAD) reports first-quarter fiscal 2019 results, with the bottom line lagging estimates. However, the stock is witnessing increased momentum from the pending merger with Albertsons.

                                      Rite Aid-Albertsons Deal: US SEC Sanctions Proxy Materials

                                      by Zacks Equity Research

                                      Rite Aid (RAD) is moving closer to completing its previously announced merger with Albertsons. The company's shareholders are going to cast their votes regarding the deal on Aug 9.

                                        Gourav Kanti Bagchi headshot

                                        RAD vs. WBA Which is a Better Stock Ahead of Earnings?

                                        by Gourav Kanti Bagchi

                                        Both Rite Aid and Walgreens Boots Alliance are scheduled to report earnings results on Jun 27 and Jun 28, respectively.

                                          Urmimala Biswas headshot

                                          Walgreens-GE Faceoff: How Impactful is it for Dow Investors?

                                          by Urmimala Biswas

                                          The stock performance of Walgreens Boots (WBA) currently does not offer much conviction. Over the past year, shares show a decline of 17.9%.

                                            Can Rite Aid's (RAD) Strategies Reverse Earnings Trend in Q1?

                                            by Zacks Equity Research

                                            Rite Aid's (RAD) prospects look bright, owing to the pending acquisition, solid fiscal 2019 outlook and other strategies. But we remain skeptical about near-term results due to its dismal past trends.

                                              Fred's Confirms Sale of Specialty Pharmacy Unit, Stock Up

                                              by Zacks Equity Research

                                              Fred's (FRED) implements its long-standing plans to divest specialty pharmacy segment to CVS Health Corporation.

                                                Fred's (FRED) Q4 Loss Widens Year Over Year, Stock Loses 6%

                                                by Zacks Equity Research

                                                Fred's (FRED) continues to struggle with its front store business. However, the company remains focused on turnaround.

                                                  Are Options Traders Betting on a Big Move in Rite Aid (RAD) Stock?

                                                  by Zacks Equity Research

                                                  Investors need to pay close attention to Rite Aid (RAD) stock based on the movements in the options market lately.